Julex Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Julex Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2	Closed	–	–	175
2018 Q4	$0	Buy	+2	New	+$1.21K	﹤0.01%	120

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Julex Capital Management's NKTR Position: Q1 2019 in Review

Julex Capital Management sold out of Nektar Therapeutics (NKTR) in Q1 2019, closing a stake of 2 shares.

Julex Capital Management first reported a position in NKTR in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 350 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

Julex Capital Management reported no remaining Nektar Therapeutics position as of Q1 2019 after selling out during the quarter.
Julex Capital Management sold 2 Nektar Therapeutics shares in Q1 2019.
Julex Capital Management first reported a position in Nektar Therapeutics in Q4 2018 and held it in 1 quarter.
Julex Capital Management's Nektar Therapeutics position peaked at $0 in Q4 2018.
350 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on Julex Capital Management's 13F filing for Q1 2019, filed 15 May 2019.